May 8 (Reuters) - Drugmaker Endo International Plc reported a bigger quarterly loss on Tuesday, hurt by an impairment charge and a fall in sales of its generic drugs.
The company recorded an asset impairment charge of $448.4 million.
Net loss attributable to shareholders was $505.5 million, or $2.26 per share in the first quarter ended March 31, compared with a loss of $173.8 million or 78 cents per share a year earlier.
Revenue fell to $700.5 million from $1.04 billion. (Reporting by Tamara Mathias in Bengaluru; Editing by Shailesh Kuber)